Vertex Pharmaceuticals (VRTX) Non Operating Income (2012 - 2018)

Vertex Pharmaceuticals' Non Operating Income history runs 7 years deep, the most recent figure standing at -$4.8 million for Q4 2018.

• On a quarterly basis, Non Operating Income rose 61.96% year-over-year to -$4.8 million in Q4 2018; TTM through Dec 2018 was -$34.1 million, a 40.71% increase from a year earlier, with the FY2018 full-year figure at -$34.1 million, up 40.71% from the prior year.
• Non Operating Income improved to -$4.8 million in Q4 2018 per VRTX's latest filing, from -$8.1 million in the prior quarter.
• Across five years, Non Operating Income topped out at -$4.8 million in Q4 2018 and bottomed at -$21.3 million in Q1 2015.
• The 5-year median for Non Operating Income is -$18.5 million (2016), against an average of -$16.5 million.
• Across the five-year window, Non Operating Income slumped 19500.0% in 2014 and jumped 61.96% in 2018, its largest moves.
• Year by year, Non Operating Income stood at -$21.2 million in 2014, then increased by 2.47% to -$20.7 million in 2015, then gained by 1.04% to -$20.4 million in 2016, then jumped by 38.61% to -$12.5 million in 2017, then soared by 61.96% to -$4.8 million in 2018.
• Per Business Quant, the three latest VRTX Non Operating Income figures stand at -$4.8 million (Q4 2018), -$8.1 million (Q3 2018), and -$10.1 million (Q2 2018).